Please select the option that best describes you:
How would you approach an MSI-H HPV+ T2 N1 squamous cell carcinoma of the anus?
Would you offer as first line treatment mitomycin/5FU with radiation or single agent immunotherapy?
Answer from: Medical Oncologist at Academic Institution
I would agree with Dr. @Noelle K. LoConte's comments but want to add one point. Some patients with Lynch Syndrome may develop HPV+ Anal SCC and in this situation, the tumor could be dMMR (most likely) but also could be pMMR (uncommon but can happen). I am not sure if dMMR is the driver for the Anal ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
For non-metastatic, potentially curable anal cancer, I would use radiation/5FU/mitomycin, and strongly consider participation in the DECREASE phase II clinical trial (NCT04166318). For metastatic disease, I would consider EA2176 (NCT04444921), a phase III trial of carboplatin/Taxol +/- nivolumab.